Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367453 | 1.00 | CES1 (0.54) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL1232452 | 1.00 | CES1 (0.54) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11671741 | 0.84 | CES1 (0.61) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11671738 | 0.84 | CES1 (0.61) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL5072437 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL6067697 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL1562541 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL1562534 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL10589355 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL585335 | 0.82 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530540-B2 | Curable composition for imprints, patterning method and pattern | FUJIFILM CORPORATION (JP) | 2013-09-10 | — | — | US | claimed |
| US-7118760-B2 | Esters of aryl benzimidazole sulfonic acids and sunscreen compositions containing same | AVON PRODUCTS, INC. (US) | 2006-10-10 | — | — | US | claimed |
| WO-2005065154-A2 | NOVEL ESTERS OF ARYL BENZIMIDAZOLE SULFONIC ACIDS AND SUNSCREEN COMPOSITIONS CONTAINING SAME | AVON PRODUCTS, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050136014-A1 | Novel esters of aryl benzimidazole sulfonic acids and sunscreen compositions containing same | AVON PRODUCTS INC. | 2005-06-23 | — | — | US | claimed |
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | claimed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | claimed |
| JP-3052961-A | — | — | None | — | — | JP | disclosed |
| CN-115023413-B | Rearrangement of dimethylphenylacrylate using zeolite | 帝斯曼知识产权资产管理有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-115023413-B | Rearrangement of dimethylphenylacrylate using zeolite | 帝斯曼知识产权资产管理有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024111521-A1 | CURABLE COMPOSITION, FILM FORMING METHOD AND ARTICLE MANUFACTURING METHOD | CANON KABUSHIKI KAISHA (JP) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-0344276-B1 | METHODS AND DEVICES FOR CONDUCTING ASSAYS | BOEHRINGER MANNHEIM CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0535849-A2 | Thermoplastic elastomers based on polyester and EPDM rubber | GENERAL ELECTRIC COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5073341-A | Immunology, diagnosis | BIOTOPE, INC. (US) | 1991-12-17 | — | — | US | disclosed |
| JP-H0352961-A | MOLDED ARTICLE FOR COLORED FOOD | MITSUBISHI PETROCHEM CO LTD | 1991-03-07 | — | — | JP | disclosed |
| EP-0344276-A1 | METHODS AND DEVICES FOR CONDUCTING ASSAYS | BOEHRINGER MANNHEIM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4868130-A | DENSITY SEPARATION | BIOTOPE, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| WO-1989005456-A1 | METHODS AND DEVICES FOR CONDUCTING ASSAYS | BIOTOPE, INC. (US) | 1989-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136014-A1 | Novel esters of aryl benzimidazole sulfonic acids and sunscreen compositions containing same | TYR, NISCH, CUTA | CES1 146/4885CES2 1072/4885TSHR 3264/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | CES1 438/4885CES2 665/4885TSHR 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.